menu
    • menu
    [{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"Carmot Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Demerger","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kimia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kimia Therapeutics \/ Carmot Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kimia Therapeutics \/ Carmot Therapeutics"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":3.1000000000000001,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Series E Financing","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":3.1000000000000001,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Series D Financing","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ The Column Group","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Petrelintide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":5.2999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":5.2999999999999998,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ F. Hoffmann-La Roche"}]

    Find Clinical Drug Pipeline Developments & Deals for CT-388

    Menu

    CT-388

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zealand Pharma

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Petrelintide,CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $5,300.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Roche & Zealand Partner to Develop Petrelintide for Obesity & Overweight Therapy

                            Details : The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : $1,650.0 million

                            March 12, 2025

                            Lead Product(s) : Petrelintide,CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $5,300.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

                            Details : CT-388 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 08, 2024

                            Lead Product(s) : CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

                            Details : CT-388 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 29, 2024

                            Lead Product(s) : CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            ACI Convention
                            Not Confirmed

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Roche Reports Positive Phase I Results For CT-388 In Obesity

                            Details : CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist, which is being developed for the treatment of obesity and type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 16, 2024

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Genentech

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Genentech

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Genentech Reports Positive Phase Ib Results For CT-388 In Obesity

                            Details : CT-388, a dual GLP-1/GIP receptor agonist, weekly subcutaneous injection is being evaluated in the Phase I clinical trial studies for the treatment of obesity and type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 16, 2024

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $3,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Carmot Therapeutics Announces Completion of Acquisition by Roche

                            Details : Roche will enhance its portfolio with Carmot’s GLP-1/GIP receptor agonists, including CT-388, CT-996, and CT-868, for metabolic diseases like obesity and diabetes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : $2,700.0 million

                            January 29, 2024

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $3,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $3,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Carmot Therapeutics Enters into Definitive Merger Agreement with Roche

                            Details : Through the acquisition, Roche will build its portfolio by adding Carmot’s pipeline of GLP-1/GIP receptor agonist, including CT-388, CT-996 and CT-868 which are being evaluated for the treatment of metabolic diseases including obesity and diabetes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : $2,700.0 million

                            December 04, 2023

                            Lead Product(s) : CT-388

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $3,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Obesity and Diabetes Biotech Carmot Therapeutics Files for IPO

                            Details : The net proceeds will be used to advance the clinical development of CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, for the treatment of type-2 diabetes and obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 17, 2023

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Carmot Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Deep Track Capital

                            Deal Size : $150.0 million

                            Deal Type : Series E Financing

                            DEALS_DEV arrow-down

                            Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for...

                            Details : The proceeds will be used to strengthen Carmot's portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis, including CT-388, a dual GLP-1/GIP receptor modulator for obese adults with and withou...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            May 25, 2023

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Deep Track Capital

                            Deal Size : $150.0 million

                            Deal Type : Series E Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kimia Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Kimia Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Carmot Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Demerger

                            DEALS_DEV arrow-down

                            Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease

                            Details : The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            January 05, 2023

                            Lead Product(s) : CT-388

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Carmot Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Demerger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth